Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
INTRA-CELL THRP (NASDAQ: ITCI) Delayed: 131.87 --0 (-0%)
Previous Close $131.87    52 Week High $59.96 
Open $131.87    52 Week Low $10.80 
Day High $131.87    P/E N/A 
Day Low $131.87    EPS $0.00 
Volume 73,876